Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07133074 · ClinicalTrials.gov registry record · Phase 4
Allergy Delabeling in Antibiotic Stewardship - Intervention
A Phase 4 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 3,800
- Enrollment target
NCT07133074 is a Phase 4 study that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 3,800 participants.
The verdict
NCT07133074, a Phase 4 study, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 3,800 participants
- Enrollment target
Study Summary
The overall goal of the RENEW-IN intervention is to assess the impact of a BL allergy delabeling intervention on antibiotic use and clinical outcomes in patients with a hematologic malignancy.
Interventions
- DIAGNOSTIC_TEST RENEW-IN Algorithm for assessment of a beta-lactam intervention
- OTHER EMR Review
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,800 participants |
| Start Date | 2026-04-20 |
| Est. Completion | 2029-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07133074
The ClinicalTrials.gov registry entry for NCT07133074 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 3,800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which RENEW-IN Algorithm for assessment of a beta-lactam intervention is the first listed.
NCT07133074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07133074 about?
NCT07133074 is a clinical study titled "Allergy Delabeling in Antibiotic Stewardship - Intervention". The overall goal of the RENEW-IN intervention is to assess the impact of a BL allergy delabeling intervention on antibiotic use and clinical outcomes in patients with a hematologic malignancy.
What is the current status of trial NCT07133074?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 3,800 participants. The study started on 2026-04-20. Estimated completion is 2029-11.
What interventions are being tested in trial NCT07133074?
The interventions under investigation include: RENEW-IN Algorithm for assessment of a beta-lactam intervention (DIAGNOSTIC_TEST), EMR Review (OTHER).
Who is sponsoring clinical trial NCT07133074?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.